Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months. A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor[…]
Overall Survival
Clinical Trial Investigates Multimodality Treatment for Pleural and Peritoneal Mesothelioma
Researchers at the Memorial Sloan Kettering Cancer Center are collaborating with Pfizer to study the effects of immunotherapy treatment Avelumab when combined with stereotactic body radiation therapy, or SBRT, for those suffering from mesothelioma. SBRT treatments use a device called a linear accelerator that delivers precise and intense doses of[…]
Multimodality Therapy in Pleural Mesothelioma
Even though there is no cure for mesothelioma, there are many different treatment options for those suffering from this almost always fatal cancer. Palliative therapy has been successful in lessening symptoms and making the patient more comfortable. Chemotherapy, radiation therapy, and surgery are treatment methods that can be successful on[…]
An Inaccurate Mesothelioma Prognosis Can Result in Wrong Treatment
Mesothelioma is not easy to diagnose. Symptoms often mimic other ailments and patients often do not make the connection between asbestos exposure and their illness. Once mesothelioma is diagnosed, patients are often given a poor prognosis – typically less than one year. However, with recent advancements in treatments and immunotherapies,[…]
